Health & Fitness
Health and Fitness
Health and Fitness
Mon, October 17, 2011
Sun, October 16, 2011
Sat, October 15, 2011
Fri, October 14, 2011
Funding Security Critical to Long Term Success of Biotech Firms
October 14, 2011 08:16 ET
Funding Security Critical to Long Term Success of Biotech Firms
The Bedford Report Provides Equity Research on MannKind and Marina Biotech
NEW YORK, NY--(Marketwire - Oct 14, 2011) - The biotech industry is generating significant investor interest this year as an influx of new and lucrative therapies work their way towards regulatory approval. While younger, unprofitable firms are having difficulty securing funding, reports suggest biotech companies with promising pipelines should be able to secure necessary capital. The Bedford Report examines the outlook for companies in the biotechnology industry and provides equity research on MannKind Corporation (
[ www.bedfordreport.com/MNKD ]
[ www.bedfordreport.com/MRNA ]
According to a recent report from Ernst & Young, US biotech companies raised $25 billion last year -- a 15 percent jump over the previous year and the highest amount since 2007. Of concern is that more than 82 percent of that funding went to 20 percent of the companies. Younger, unprofitable companies in the US that depend on funding from venture capital firms, stock sales and partnerships saw available capital decline 21 percent in 2010.
The Bedford Report releases investment research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous analyst reports and industry newsletters.
The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Analysis by the professional services firm BDO argues that larger pharmaceutical firms are increasing reliance on biotech companies to fill their pipelines, which has been a net positive for small biotech companies.
According to Thomson Reuters, on average biotech companies in the NASDAQ Biotechnology Index (NBI) spent $54 million on R&D in 2010, reflecting a 7 percent decline from 2009.
The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at [ http://www.bedfordreport.com/disclaimer ].
